Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury

Critical Care

Volumn 14, Issue 2, 2010, Pages

  Grottke, Oliver ^a   Braunschweig, Till ^a   Henzler, Dietrich ^b   Coburn, Mark ^a   Tolba, Rene ^a   Rossaint, Rolf ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; HAEMOCOMPLETAN; HEMOGLOBIN; HETASTARCH; PLACEBO; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BLUNT TRAUMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EMBOLISM; ERYTHROCYTE TRANSFUSION; HEMATOLOGICAL PARAMETERS; HEMODILUTION; HEMODYNAMICS; HISTOLOGY; IN VIVO STUDY; LIVER INJURY; MALE; MICROTHROMBUS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SWINE; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY; TREATMENT OUTCOME; ANIMAL; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED DISORDER; INJURY; LIVER; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZATION; VASCULARIZATION;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; FIBRINOGEN; HEMODILUTION; HEMORRHAGE; LIVER; MODELS, ANIMAL; RANDOM ALLOCATION; SWINE; WOUNDS, NONPENETRATING;

EID: 77950688158     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8960     Document Type: Article

References (39)

1. Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, Kluger Y, Mackway-Jones K, Parr MJ, Rizoli SB, Yukioka T, Hoyt DB, Bouillon B. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008, 65:748-754. 10.1097/TA.0b013e3181877a9c, 18849786.
2. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, Innerhofer P. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg 2007, 105:905-917. 10.1213/01.ane.0000280481.18570.27, 17898365.
3. Fenger-Eriksen C, Anker-Møller E, Heslop J, Ingerslev J, Sørensen B. Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth 2005, 94:324-329. 10.1093/bja/aei052, 15608046.
4. Hiippala ST, Myllylä GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995, 81:360-365. 10.1097/00000539-199508000-00026, 7542432.
5. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Gordini G, Stahel PF, Hunt BJ, Komadina R, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R, . Task Force for Advanced Bleeding Care in Trauma Management of bleeding following major trauma: a European guideline. Crit Care 2007, 11:R17. 10.1186/cc5686, 2151863, 17298665, Task Force for Advanced Bleeding Care in Trauma.
6. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM, . British Committee for Standards in Haematology, Blood Transfusion Task Force Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004, 126:11-28. 10.1111/j.1365-2141.2004.04972.x, 15198728, British Committee for Standards in Haematology, Blood Transfusion Task Force.
7. Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009, 23:177-188. 10.1016/j.tmrv.2009.03.001, 19539873.
8. Fries D, Krismer A, Klingler A, Streif W, Klima G, Wenzel V, Haas T, Innerhofer P. Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth 2005, 95:172-177. 10.1093/bja/aei160, 15923269.
9. Fries D, Innerhofer P, Reif C, Streif W, Klingler A, Schobersberger W, Velik-Salchner C, Friesenecker B. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: an in vitro model. Anesth Analg 2006, 102:347-351. 10.1213/01.ane.0000194359.06286.d4, 16428520.
10. Haas T, Fries D, Velik-Salchner C, Reif C, Klingler A, Innerhofer P. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesth Analg 2008, 106:1360-1365. 10.1213/01.ane.0b013e3181684339, 18420845.
11. Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009, 102:793-799. 10.1093/bja/aep098, 19420005.
12. Ruggeri ZM. The role of von Willebrand factor and fibrinogen in the initiation of platelet adhesion to thrombogenic surfaces. Thromb Haemost 1995, 74:460-463.
13. Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997, 78:611-616.
14. Guide for the care and use of laboratory animals. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council 1996, Washington DC: National Academy Press, 7.
15. Bush JA, Jesen WN, Cartwright GE, Wintrobe MM. Blood volume studies in normal and anemic swine. Am J Physiol 1955, 181:9-14.
16. Moore EE, Cogbill TH, Jurkovich GJ, Shackford SR, Malangoni MA, Champion HR. Organ injury scaling: spleen and liver (1994 revision). J Trauma 1995, 38:323-324. 10.1097/00005373-199503000-00001, 7897707.
17. Grottke O, Braunschweig T, Philippen B, Gatzweiler KH, Gronloh N, Staat M, Rossaint R, Tolba R. A new model for blunt liver injuries in the swine. Eur Surg Res 2010, 44:65-73. 10.1159/000265053, 19996600.
18. Hiippala ST. Dextran and hydroxyethyl starch interfere with fibrinogen assays. Blood Coagul Fibrinolysis 1995, 6:743-746. 10.1097/00001721-199512000-00008, 8825225.
19. Lang T, Toller W, Gütl M, Mahla E, Metzler H, Rehak P, März W, Halwachs-Baumann G. Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. J Thromb Haemost 2004, 2:147-153. 10.1111/j.1538-7836.2004.00555.x, 14717978.
20. Velik-Salchner C, Schnürer C, Fries D, Müssigang PR, Moser PL, Streif W, Kolbitsch C, Lorenz IH. Normal values for thrombelastography (ROTEM) and selected coagulation parameters in porcine blood. Thromb Res 2006, 117:597-602. 10.1016/j.thromres.2005.05.015, 15985284.
21. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996, 88:907-914.
22. Velik-Salchner C, Haas T, Innerhofer P, Streif W, Nussbaumer W, Klingler A, Klima G, Martinowitz U, Fries D. The effect of fibrinogen concentrate on thrombocytopenia. J Thromb Haemost 2007, 5:1019-1025. 10.1111/j.1538-7836.2007.02481.x, 17461931.
23. Lang T, Johanning K, Metzler H, Piepenbrock S, Solomon C, Rahe-Meyer N, Tanaka KA. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg 2009, 108:751-758. 10.1213/ane.0b013e3181966675, 19224779.
24. Nielsen VG, Gurley WQ, Burch TM. The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth Analg 2004, 99:120-123. 10.1213/01.ANE.0000123012.24871.62, 15281516.
25. Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thrombelastography. Thromb Res 2001, 104:467-474. 10.1016/S0049-3848(01)00395-4, 11755957.
26. Nielsen VG, Cohen BM, Cohen E. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand 2005, 49:222-231. 10.1111/j.1399-6576.2005.00602.x, 15715625.
27. Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia 2006, 12:48-52. 10.1111/j.1365-2516.2006.01366.x, 17123394.
28. Kheirabadi BS, Crissey JM, Deguzman R, Holcomb JB. In vivo bleeding time and in vitro thrombelastography measurements are better indicators of dilutional hypothermic coagulopathy than prothrombin time. J Trauma 2007, 62:1352-1359. 10.1097/TA.0b013e318047b805, 17563647.
29. Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan CK, Royston BD, Bridges CR, Higgins RS, Despotis G, Brown JR, Spiess BD, Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E, Hill SE, Body S. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007, 83:S27-S86. 10.1016/j.athoracsur.2007.02.099, 17462454, Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion.
30. Schols SE, Feijge MA, Lancé MD, Hamulyák K, ten Cate H, Heemskerk JW, van Pampus EC. Effects of plasma dilution on tissue-factor-induced thrombin generation and thromboelastography: partly compensating role of platelets. Transfusion 2008, 48:2384-2394. 10.1111/j.1537-2995.2008.01872.x, 18673348.
31. Jesty J, Beltrami E. Positive feedbacks of coagulation: their role in threshold regulation. Arterioscler Thromb Vasc Biol 2005, 25:2463-2469. 10.1161/01.ATV.0000187463.91403.b2, 16179597.
32. Schols SE, Meijden PE, van Oerle R, Curvers J, Heemskerk JW, van Pampus EC. Increased thrombin generation and fibrinogen level after therapeutic plasma transfusion: relation to bleeding. Thromb Haemost 2008, 99:64-70.
33. Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, Sibony O, Mahieu-Caputo D, Hurtaud-Roux MF, Huisse MG, Denninger MH, de Prost D, . PPH Study Group The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007, 5:266-273. 10.1111/j.1538-7836.2007.02297.x, 17087729, PPH Study Group.
34. Karlsson M, Ternström L, Hyllner M, Baghaei F, Flinck A, Skrtic S, Jeppsson A. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost 2009, 102:137-144.
35. Rahe-Meyer N, Pichlmaier M, Haverich A, Solomon C, Winterhalter M, Piepenbrock S, Tanaka KA. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth 2009, 102:785-792. 10.1093/bja/aep089, 2683341, 19411671.
36. Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tønnesen E, Ingerslev J, Sørensen B. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 2009, 7:795-802. 10.1111/j.1538-7836.2009.03331.x, 19320829.
37. Tatli E, Ozcelik F, Aktoz M. Plasma fibrinogen level may predict critical coronary artery stenosis in young adults with myocardial infarction. Cardiol J 2009, 16:317-320.
38. Dickneite G, Pragst I, Joch C, Bergman GE. Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). Blood Coagul Fibrinolysis 2009,
39. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010, CCD007594.